of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information:www.galderma.com.

References:


Ständer S, et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis Phase 3 studies.JEADV. 2025 Early View. doi: 10.1111/jdv.70250

Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.J Allergy Clin Immunol. 2020;145(1): 173-182. d
=*=*=*=*=*=
当前为第10/16页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页